Description:

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the neurological sub-cohort. If a text field can't be filled out, note 'ND'.

Link:
https://leoss.net
Keywords:
  1. 10/31/20 10/31/20 -
  2. 11/27/20 11/27/20 -
  3. 5/7/21 5/7/21 -
  4. 5/27/21 5/27/21 - Sarah Riepenhausen
  5. 5/27/21 5/27/21 - Sarah Riepenhausen
Copyright Holder:
LEOSS
Uploaded on:

May 27, 2021

DOI:
To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients

Neurological sub-cohort

Duration of neurological comorbidity
Disease duration
Pre-existing neurological medication
None
Antidementive drugs
Antidepressant drugs
Antiepileptic drugs
Antipsychotic drugs
Antiparkinsonian drugs, Levodopa
Antiparkinsonian drugs, Dopamine Agonists
Other Antiparkinsonian drugs
CNS acting drugs, Riluzole
Other CNS acting drugs
Unknown
Neurological status
Neurological status prior to current illness: History of Gait
Neurological status prior to current illness: History of falls
Neurological status prior to current illness: Cognitive status
Neurological status prior to current illness: Speech
Neurological status prior to current illness: Swallowing
Neurological status prior to current illness: Respiration
Previous nursing need
Specification of the indicated other neurological comorbidities
Brain tumor
Encephalitis
Epilepsy
Hemorrhagic Stroke
Ischemic Stroke
Meningitis
Migraine
Myasthenia, bulbar
Myasthenia, generalized
Myasthenia, ocular
Myositis
Sinus/venous Thrombosis
Subarachnoid bleeding
Transitory ischemic attack (TIA)
Other neurological comorbidities
Unknown
Specification of indicated cerebrovascular disease
Hemorrhagic stroke: Pattern of bleeding
Ischemic stroke: Most likely cause of stroke (TOAST)
YYYY
Modified rankin scale at admission
Atrial fibrillation
Internal carotid artery stenosis > 50 %
Cerebrovascular disease: Medication
Aspirin
Statins
Warfarin / marcumar
Dabigatran
Apixaban
Rivaroxaban
Edoxaban
Clopidogrel
None
Unknown
Multiple Sclerosis subtype & severity
Multiple Sclerosis subtype
Severity of Multiple Sclerosis at Baseline
B-cells at Baseline
Multiple Sclerosis: Immunomodulatory medication at Baseline
Alemtuzumab
Azathioprine
Beta-Interferon
Cladribine
Dimethyl fumarate
Fingolimod
Glatiramer acetate
Intravenous immunoglobuline
Low dose Corticosteroids (<100 mg Prednisolone equivalent / d)
Mitoxantrone
Natalizumab
Ocrelizumab
Rituximab
Siponimod
Teriflunomide
Other Immunomodulatory medication
Unknown
None
MS: Adjustments of immunomodulatory therapy in the context of COVID-19
Discontinued immunomodulatory therapy
weeks
Multiple Sclerosis: Relapse treatment in the last three months
Multiple Sclerosis: Relapse treatment in the last three months
Neurodegeneration
Indicate type of Dementia
Indicate type of movement disorder
Indicate Motoneuron Disease
Cognitive / neuropsychiatric impairment during the course of COVID-19
Memory deficit: Indicate the phase of occurrence
Apraxia: Indicate the phase of occurrence
Neglect: Indicate the phase of occurrence
Impaired orientation: Indicate the phase of occurrence
Other cognitive/neuropsychiatric impairment
Visual impairment during the course of COVID-19
Impaired visual field: Indicate the phase of occurrence
Impaired visual acuity: Indicate phase of occurrence
Oculomotoric impairment during the course of COVID-19
Double vision / Palsy of gaze: Indicate the phase of occurrence
Cranial nerve III (N. oculomotorius): Indicate phase of occurrence
Cranial nerve IV (N. trochlearis): Indicate phase of occurrence
Cranial nerve VI (N. abducens): Indicate phase of occurrence
Supranuclear gaze palsy (e.g. internuclear ophthalmopglegia): Indicate phase of occurrence
Nystagmus: Indicate phase of occurrence
Other oculomotoric impairment: Indicate phase of occurrence
Paresis during the course of COVID-19
Paresis left arm: Indicate phase of occurrence
Paresis right arm: Indicate phase of occurrence
Paresis left leg: Indicate phase of occurrence
Paresis right leg: Indicate phase of occurrence
Other paresis: Please indicate phase of occurrence
Abnormal muscle reflexes during the course of COVID-19
Depressed muscle reflexes: Please indicate the phase of occurrence
Increased muscle reflexes: Please indicate the phase of occurrence
Sensory deficit during the course of COVID-19
Focal sensory deficit: Please indicate the phase of occurrence
Peripheral symmetric sensory deficit: Please indicate the phase of occurrence
Other sensory deficit: Please indicate the phase of occurrence
Other neurological findings during the course of COVID-19
Aphasia: Please indicate the phase of occurrence
Dysarthria: Indicate the phase of occurrence
Facial Palsy: Indicate the phase of occurrence
Swallowing impaired: Indicate the phase of occurrence
Vertigo: Indicate the phase of occurrence
Neuralgia: Indicate the phase of occurrence
Positive pyramidal signs (e.g. Babinski): Please indicate the phase of occurrence
Ataxia: Indicate the phase of occurrence
Unsteady gait: Indicate the phase of occurrence
Neurological diagnostics: cCT & cMRI
cCT in Uncomplicated phase
cCT in Complicated phase
cCT in Critical phase
cMRI in Uncomplicated phase
cMRI in Complicated phase
cMRI in Critical phase
Neurological diagnostics: EEG
EEG in Uncomplicated phase
EEG in Complicated phase
EEG in Critical phase
Neurological diagnostics: Electrophysiology
Electrophysiology in Uncomplicated phase
Electrophysiology in Complicated phase
Electrophysiology in Critical phase
Neurological diagnostics: Spinal tap - cerebrospinal fluid
Cell count in Uncomplicated phase
Cell count in Complicated phase
Cell count in Critical phase
Glucose concentration in Uncomplicated phase
Glucose concentration in Complicated phase
Glucose concentration in Critical phase
Lactate concentration in Uncomplicated phase
Lactate concentration in Complicated phase
Lactate concentration in Critical phase
Protein concentration in Uncomplicated phase
Protein concentration in Complicated phase
Protein concentration in Critical phase
Oligoclonal bands type in Uncomplicated phase
Oligoclonal bands type in Complicated phase
Oligoclonal bands type in Critical phase
Neurological diagnostics: Spinal tap - pathogens
Bacteria
Fungi
Virus
Antineuronal Antibody Status
Indicate the phase in which the above indicated pathogen and antibody testing status was performed
Is data entry for this section finished?
Is data entry for this section finished?

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial